References

Maternal psychological distress a mental health service use during the COVID-19 pandemic

10.1016/j.jad.2020.07.081 · 2020 · External reference

High anxiety and health-related quality of life in families with children with food allergy during coronavirus disease 2019

10.1016/j.anai.2020.09.010 · 2021 · External reference

COVID-19-related media consumption and parental mental health

10.1037/cbs0000280 · 2021 · External reference

eHealth literacy: essential skills for consumer health in a networked world

10.2196/jmir.8.2.e9 · 2006 · External reference

Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases

10.1080/21645515.2020.1780846 · 2020 · External reference

Vaccine hesitancy: the next challenge in the fight against COVID-19

10.1007/s10654-020-00671-y · 2020 · External reference

10.15585/mmwr.mm7004e1

10.15585/mmwr.mm7004e1 · External reference

The safety profile of COVID-19 vaccinations in the United States

10.1016/j.ajic.2021.10.015 · 2022 · External reference

10.1016/j.jaip.2021.04.025

10.1016/j.jaip.2021.04.025 · External reference

Experience of the first 1127 COVID-19 vaccine allergy safety patients in Hong Kong - clinical outcomes, barriers to vaccination, and urgency for reform

10.1016/j.waojou.2021.100622 · 2022 · External reference

Vaccine hesitancy and (fake) news: quasi-experimental evidence from Italy

10.1002/hec.3937 · 2019 · External reference

Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: early report

10.1016/j.anai.2021.03.012 · 2021 · External reference

Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?

10.1111/all.14711 · 2021 · External reference

Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis

10.1111/all.15183 · 2022 · External reference

Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions

10.1016/j.anai.2021.11.006 · 2022 · External reference

Second-dose COVID-19 vaccines are well tolerated in patients with allergic reactions to the first dose - a single center experience

10.1016/j.waojou.2022.100654 · 2022 · External reference

Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity

10.1111/all.15414 · 2022 · External reference

Successful mRNA COVID-19 vaccination in a patient with a history of severe polyethylene glycol anaphylaxis

10.1186/s13223-022-00698-8 · 2022 · External reference

Scoping studies: towards a methodological framework

10.1080/1364557032000119616 · 2005 · External reference

PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation

10.7326/m18-0850 · 2018 · External reference

Vaccine confidence amongst those living with allergy during the COVID pandemic (ACCORD): a scoping review protocol

10.1186/s13223-022-00723-w · 2022 · External reference

PRESS peer review of electronic search strategies: 2015 guideline statement

10.1016/j.jclinepi.2016.01.021 · 2016 · External reference

Acute allergic reactions to mRNA COVID-19 vaccines

10.1001/jama.2021.3976 · 2021 · External reference

Surveillance for adverse events after COVID-19 mRNA vaccination

10.1001/jama.2021.15072 · 2021 · External reference

Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system

10.1001/jamanetworkopen.2021.25524 · 2021 · External reference

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don’t give up on the second dose!

10.1111/all.14958 · 2021 · External reference

Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience

10.1016/j.anai.2021.10.019 · 2022 · External reference

Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19

10.1111/imj.15623 · 2022 · External reference

Adverse reactions and safety profile of the mRNA COVID-19 vaccines among Asian military personnel

10.47102/annals-acadmedsg.2021345 · 2021 · External reference

Adverse reactions following COVID-19 vaccination: an Ecuadorian experience

10.1016/j.amsu.2021.103044 · 2021 · External reference

Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination

10.1016/j.jaip.2021.05.031 · 2021 · External reference

COVID-19 vaccination reactogenicity in persons with multiple sclerosis

10.1212/nxi.0000000000001104 · 2022 · External reference

Three doses of COVID-19 mRNA vaccination are safe based on adverse events reported in electronic health records

2021 · External reference

An mRNA vaccine against SARS-CoV-2 - preliminary report

10.1056/nejmoa2022483 · 2020 · External reference

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

10.1056/nejmoa2034577 · 2020 · External reference

Efficacy and safety of the mRNA-1273 SARS-CoV-2 caccine

10.1056/nejmoa2035389 · 2021 · External reference

Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico

10.1056/nejmoa2116185 · 2022 · External reference

Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine

10.1056/nejmoa2105290 · 2021 · External reference

Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine

10.1056/nejmoa2201300 · 2022 · External reference

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

10.1016/s0140-6736(21)01429-x · 2021 · External reference

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

10.1016/s0140-6736(20)32661-1 · 2021 · External reference

Association of self-reported high-risk allergy history with allergy symptoms after COVID-19 vaccination

10.1001/jamanetworkopen.2021.31034 · 2021 · External reference

Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US–December 14, 2020-January 18, 2021

10.1001/jama.2021.1967 · 2021 · External reference

Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine

10.1016/j.vaccine.2021.09.048 · 2021 · External reference

Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk

10.1001/jamanetworkopen.2021.22255 · 2021 · External reference

Skin adverse reactions to novel messenger RNA coronavirus vaccination: a case series

10.3390/diseases9030058 · 2021 · External reference

Delayed systemic urticarial reactions following mRNA COVID-19 vaccination

10.2500/aap.2022.43.210101 · 2022 · External reference

Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers

10.1080/00325481.2021.1999708 · 2022 · External reference

Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site

10.1016/j.vaccine.2021.06.061 · 2021 · External reference

The polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients

10.1111/cea.14064 · 2022 · External reference

Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States

10.1016/j.anai.2021.04.004 · 2021 · External reference

Analysis of COVID-19 vaccine type and adverse effects following vaccination

10.1001/jamanetworkopen.2021.40364 · 2021 · External reference

Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study

10.1016/j.dsx.2021.102207 · 2021 · External reference

Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): a prospective cohort study with intensive monitoring

10.1016/j.vaccine.2022.01.062 · 2022 · External reference

Safety of COVID-19 vaccines

10.1002/jmv.27214 · 2021 · External reference

Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health-care system experience

10.2500/aap.2021.42.210069 · 2021 · External reference

Local and systemic adverse effects of CoronaVac vaccine in risk groups: prospective, cross-sectional study

10.5336/dermato.2021-85208 · 2021 · External reference

The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine

10.1111/all.15148 · 2021 · External reference

An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history

10.1016/j.jaip.2021.07.010 · 2021 · External reference

Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine

10.1111/cea.13874 · 2021 · External reference

Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19

10.1016/j.jaip.2021.07.012 · 2021 · External reference

Unresolved reference

External reference

Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose

10.1001/jamainternmed.2021.3779 · 2021 · External reference

Acceptance and attitude toward COVID-19 vaccination among the public in Saudi Arabia: a cross-sectional study

10.5005/jp-journals-10024-3114 · 2021 · External reference

Survey of adult and paediatric rheumatology patients suggests information about COVID-19 vaccination will aid uptake

10.1093/rheumatology/keab169 · 2021 · External reference

The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey

10.1016/j.ejca.2021.05.006 · 2021 · External reference

Assessment of COVID-19 vaccines acceptance in the Lebanese population: a national cross-sectional study

10.1186/s40545-021-00403-x · 2022 · External reference

Survey on attitude towards COVID-19 vaccines and analysis of reasons for vaccine hesitancy among public in Tamil Nadu during the second wave of COVID-19 pandemic

2021 · External reference

Analyzing the attitude of Indian citizens towards COVID-19 vaccine - a text analytics study

10.1016/j.dsx.2021.02.031 · 2021 · External reference

The perception and attitudes toward COVID-19 vaccines: a cross-sectional study in Poland

10.3390/vaccines9040382 · 2021 · External reference

Public willingness and determinants of COVID-19 vaccination at the initial stage of mass vaccination in China

10.3390/vaccines9101172 · 2021 · External reference

Healthcare provider attitudes toward the newly developed COVID-19 vaccine: cross-sectional study

10.3390/nursrep11010018 · 2021 · External reference

First-dose coronavirus 2019 vaccination coverage among the residents of long-term care facilities in France

10.1159/000517793 · 2022 · External reference

Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China

10.1080/14760584.2022.2016401 · 2022 · External reference

COVID-19 vaccination in Chinese children: a cross-sectional study on the cognition, psychological anxiety state and the willingness toward vaccination

10.1080/21645515.2021.1949950 · 2022 · External reference

The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach

10.1016/j.jaip.2021.06.006 · 2021 · External reference

Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine

10.1016/j.vaccine.2013.10.033 · 2013 · External reference

Risk of anaphylaxis after vaccination in children and adults

10.1016/j.jaci.2015.07.048 · 2016 · External reference

Covid-19: people with history of significant allergic reactions should not receive Pfizer vaccine, says regulator

10.1136/bmj.m4780 · 2020 · External reference

COVID-19 vaccination in patients with reported allergic reactions: updated evidence and suggested approach

10.1016/j.jaip.2021.03.053 · 2021 · External reference

After years of media coverage, can one more video report trigger heuristic judgments? A national study of American terrorism risk perceptions

10.1080/19434471003768826 · 2010 · External reference

The role of the affect and availability heuristics in risk communication

10.1111/j.1539-6924.2006.00773.x · 2006 · External reference

10.7249/rra112-7

10.7249/rra112-7 · External reference

Under-reporting of adverse drug reactions: a systematic review

10.2165/00002018-200629050-00003 · 2006 · External reference

Primary care provider-reported prevalence of vaccine and polyethylene glycol allergy in Canada

10.1016/j.anai.2021.05.011 · 2021 · External reference